|Bid||36.05 x 800|
|Ask||38.00 x 900|
|Day's Range||35.01 - 37.80|
|52 Week Range||23.62 - 40.24|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Late Monday, Maravai reported adjusted income of 26 cents per share on $148.21 million in sales. But the fresh IPO stock was unmoved in after-hours trading.
The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
Maravai LifeSciences Holdings, Inc. (MRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).